15,616 Shares in Karyopharm Therapeutics Inc (KPTI) Purchased by Fox Run Management L.L.C.

Fox Run Management L.L.C. purchased a new stake in Karyopharm Therapeutics Inc (NASDAQ:KPTI) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 15,616 shares of the company’s stock, valued at approximately $266,000.

Several other hedge funds also recently made changes to their positions in KPTI. Wells Fargo & Company MN increased its stake in shares of Karyopharm Therapeutics by 16.3% in the 1st quarter. Wells Fargo & Company MN now owns 36,036 shares of the company’s stock valued at $483,000 after acquiring an additional 5,062 shares during the last quarter. Prudential Financial Inc. grew its position in shares of Karyopharm Therapeutics by 259.3% in the 1st quarter. Prudential Financial Inc. now owns 68,736 shares of the company’s stock valued at $923,000 after purchasing an additional 49,606 shares during the period. Swiss National Bank grew its position in shares of Karyopharm Therapeutics by 12.8% in the 1st quarter. Swiss National Bank now owns 64,150 shares of the company’s stock valued at $861,000 after purchasing an additional 7,300 shares during the period. Schwab Charles Investment Management Inc. grew its position in shares of Karyopharm Therapeutics by 11.9% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 168,188 shares of the company’s stock valued at $2,258,000 after purchasing an additional 17,899 shares during the period. Finally, Northern Trust Corp grew its position in shares of Karyopharm Therapeutics by 3.0% in the 1st quarter. Northern Trust Corp now owns 397,294 shares of the company’s stock valued at $5,331,000 after purchasing an additional 11,577 shares during the period. 71.40% of the stock is owned by institutional investors.

In other Karyopharm Therapeutics news, major shareholder Ltd Chione sold 2,654 shares of the company’s stock in a transaction that occurred on Monday, July 16th. The stock was sold at an average price of $18.52, for a total transaction of $49,152.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Sharon Shacham sold 12,500 shares of the company’s stock in a transaction that occurred on Monday, October 8th. The stock was sold at an average price of $15.75, for a total value of $196,875.00. Following the transaction, the insider now directly owns 715,274 shares of the company’s stock, valued at approximately $11,265,565.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,056,701 shares of company stock valued at $20,864,276. Insiders own 13.26% of the company’s stock.

NASDAQ:KPTI opened at $12.60 on Friday. Karyopharm Therapeutics Inc has a twelve month low of $9.00 and a twelve month high of $21.71. The company has a market cap of $1.03 billion, a price-to-earnings ratio of -4.48 and a beta of 3.75.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Tuesday, August 7th. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.21. The firm had revenue of $19.89 million for the quarter, compared to analyst estimates of $5.97 million. Sell-side analysts expect that Karyopharm Therapeutics Inc will post -3.18 earnings per share for the current year.

Several brokerages recently issued reports on KPTI. Canaccord Genuity reiterated a “buy” rating and issued a $27.00 price objective on shares of Karyopharm Therapeutics in a research report on Tuesday, August 7th. BidaskClub lowered Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, September 29th. Zacks Investment Research lowered Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 3rd. Robert W. Baird reiterated a “buy” rating and issued a $25.00 price objective on shares of Karyopharm Therapeutics in a research report on Wednesday, August 8th. Finally, HC Wainwright reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research report on Friday, June 15th. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $22.90.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.

Recommended Story: How is a Moving Average Calculated?

Want to see what other hedge funds are holding KPTI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Karyopharm Therapeutics Inc (NASDAQ:KPTI).

Institutional Ownership by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply